Trial · NCT07479550
Study of Psilocybin Under Anesthesia Controlled by EEG
NCT07479550, Phase 2, Not yet recruiting, Stanford University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Psilocybin Under Anesthesia Controlled by EEG. Trials, record NCT07479550. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07479550
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Psilocybin Under Anesthesia Controlled by EEG
- NCT number
- NCT07479550
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 10 participants, estimated
- Lead sponsor
- Stanford University
- Conditions
- Major Depression
- Interventions
- Psilocybin (Usona Institute), Propofol, Placebo
- First posted
- 2026-03-18
- Last updated
- 2026-05-06
Source ClinicalTrials.gov
Registered outcomes32
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Blinding Success - Correct Identification of Psilocybin at Final Dosing Session | 1 day after the final dosing session (Visit 21, Week 4) | Percentage of participants who correctly guess whether they received a full dose of psilocybin during the final dosing session (Visit 20), assessed using the Blinding Survey at Visit 21. |
| Primary | Blinding Success - Accuracy of Guessed Psilocybin Dose at Final Dosing Session | 1 day after the final dosing session (Visit 21, Week 4) | The dose of psilocybin guessed by participants at Visit 21 compared to the dose actually received at Visit 20, assessed using the Blinding Survey. |
| Secondary | Acute Drug Effects by Dose - Drug Effects Questionnaire (DEQ) | Immediately after emergence at each of the 4 dosing sessions (Visits 5, 10, 15, 20; Weeks 1-4) | Mean differences in acute subjective drug effects between psilocybin doses and placebo, assessed using the Drug Effects Questionnaire (DEQ; Morean et al., 2013) after emergence from anesthesia at each dosing session. The DEQ consists of 5 items rated on visual analog scales; scores are expressed as the mean across items. Minimum score: 0 (no drug effects); Maximum score: 100 (maximum drug effects). Higher scores indicate greater perceived drug effect. |
| Secondary | Mystical-Type Experiences by Dose - Mystical Experiences Questionnaire (MEQ-30) | Immediately after emergence at each of the 4 dosing sessions (Visits 5, 10, 15, 20; Weeks 1-4) | Mean changes in overall and subsection scores of the Mystical Experiences Questionnaire (MEQ-30; Maclean et al., 2012) compared between psilocybin doses and placebo, assessed after emergence from anesthesia at each dosing session. The MEQ-30 consists of 30 items rated on a 0-5 scale across four subscales: Mystical, Positive Mood, Transcendence of Time and Space, and Ineffability. Total scores are calculated by summing all individual items. Minimum score: 0 (no mystical-type experience); Maximum score: 150 (extreme mystical-type experience). Higher scores indicate greater mystical experience intensity. |
| Secondary | Altered States of Consciousness by Dose - Three-Dimensional Altered States of Consciousness Scale (3D-ASCr) | Immediately after emergence at each of the 4 dosing sessions (Visits 5, 10, 15, 20; Weeks 1-4) | Mean changes in overall and dimension scores of the Three-Dimensional Altered States of Consciousness Rating Scale - Revised (3D-ASCr; Stocker et al., 2025) compared between psilocybin doses and placebo, assessed after emergence from anesthesia at each dosing session. The 3D-ASCr consists of 42 items rated on visual analog scales, organized into three higher-order dimensions: Positive Effects (PosE), Distressing Effects (DisE), and Perceptual Effects (PerE). Dimension scores are calculated as means of their constituent subscale means. Minimum score: 0 (no alteration); Maximum score: 100 (maximum alteration). Higher scores indicate greater alteration of consciousness in each dimension; higher PosE scores reflect more positive experiential effects, higher DisE scores reflect more distressing effects, and higher PerE scores reflect greater perceptual effects. |
| Other | Feasibility - Challenging Experiences Questionnaire (CEQ) | Immediately after emergence at Visits 5, 10, 15, and 20 (Weeks 1-4) | Descriptive statistics of challenging experiences by dose of psilocybin versus placebo, assessed using the Challenging Experiences Questionnaire - 7 Item (CEQ-7; Strickland et al., 2024) after emergence from anesthesia at each dosing session. The CEQ-7 consists of 7 items rated on a 6-point scale (0 = none/not at all; 5 = extreme), one item per challenging experience domain (Fear, Grief, Physical Distress, Insanity, Isolation, Death, Paranoia). Total scores are calculated by summing all items. Minimum score: 0; Maximum score: 35. Higher scores indicate greater challenging experience severity. |
| Other | Safety - Incidence and Severity of Adverse Events | Continuously from Visit 1 through Visit 25 (up to 7 weeks) | Incidence, severity, and CTCAE grade of adverse events, including CTCAE Grade 3 or higher cardiopulmonary, neurological, or psychiatric events, coded using MedDRA. Includes abnormal EKG and hemodynamic findings and clinically significant laboratory results. |
| Other | Safety - PACU Discharge Readiness | Within 4 hours of emergence at Visits 5, 10, 15, and 20 (Weeks 1-4) | Incidence of participants meeting post-anesthesia care unit (PACU) discharge readiness criteria within 4 hours of emergence from anesthesia at each dosing session. |
| Other | Safety - Suicidal Ideation and Behavior (C-SSRS) | From Visit 2 through Visit 25 (Screening through Week 7) | Incidence and severity of suicidal ideation and behavior assessed using the Columbia Suicide Severity Rating Scale (C-SSRS). Lifetime and Last 10 Years C-SSRS administered at screening (Visit 2); Since Last Visit C-SSRS administered at all subsequent visits. |
| Other | Safety - Positive Urine Drug Screens | Prior to each dosing session at Visits 5, 10, 15, and 20 (Weeks 1-4) | Incidence of positive urine drug screens prior to each dosing session. |
1 to 10 of 32Source ClinicalTrials.gov
See all 32 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers11
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07479550
GET https://conductscience.org/api/trials/v1/NCT07479550/registered?page=2